Cowen top analyst Ritu Baral chimes in on Cytokinetics, Inc. (NASDAQ:CYTK) after Amgen, Inc.
In light of Cytokinetics, Inc.’s (NASDAQ:CYTK) second-quarter update, JMP Securities analyst Jason Butler remains bullish for the biotech company’s pipeline drug-paved road ahead.
Analyst Charles Duncan of Piper Jaffray maintained his Overweight rating for Cytokinetics, Inc. (NASDAQ:CYTK) with a price target of $24, marking a 138% increase …
Healthcare analysts provide their insights on Endo International plc – Ordinary Shares (NASDAQ:ENDP) and Cytokinetics, Inc. (NASDAQ:CYTK) following a new patent and management …
In a research report published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Cytokinetics Inc. (NASDAQ:CYTK), with a price …
Cytokinetics, Inc. (NASDAQ:CYTK) announced the start of a double-blind, randomized, placebo-controlled, multi-center Phase 2 clinical trial to evaluate the safety, pharmacokinetics and efficacy of …
Cytokinetics, Inc. (NASDAQ:CYTK) and Origent Data Sciences, Inc.
Many investors hope to win big on biotech stocks as shares can sky rocket when there is good news. Analysts explain why there are plenty …
The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which tracks 144 biotech and pharmaceutical companies, climbed nearly 3% today, four-day win streak, helped by some encouraging …
Cytokinetics, Inc. (NASDAQ:CYTK) reported total research and development revenues for the fourth quarter of 2015 were $9.
